SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
BioTech 365
OCTOBER 5, 2021
SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio Rapid development of key mutation detection reagents continues to facilitate critical investigation and monitoring activities SYDNEY–(BUSINESS WIRE)–#COVID19–SpeeDx Pty.
Let's personalize your content